ROCO
4161
Market cap40mUSD
Oct 08, Last price
21.40TWD
1D
-0.47%
1Q
-6.96%
Jan 2017
-59.96%
IPO
-46.55%
Name
Bioptik Technology Inc
Chart & performance
P/E
17.98
P/S
1.53
EPS
1.19
Div yield, %
1.40%
Shrs. gr., 5y
2.30%
Rev. gr., 5y
11.51%
Revenues
837m
-3.25%
Net income
71m
-23.92%
CFO
44m
-72.40%
Dividend
Jul 16, 20260.7 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bioptik Technology Incorporation operates as a global entity, focusing on the creation and distribution of medical instruments and diagnostic chemicals. The company's product line encompasses the EasyMate series of blood glucose monitoring systems, as well as comprehensive diagnostic devices designed to measure blood glucose, cholesterol, and uric acid levels, complete with their essential test strips. Beyond its healthcare offerings, Bioptik also provides a range of skincare solutions, including those formulated with hyaluronic acid, alongside various dietary supplements. Uniquely, the company diversifies its business by supplying biodiesel products. Founded in 1999, Bioptik Technology Incorporation is headquartered in Zhunan, Taiwan.
Key people
Yiling Yang
Chief Executive Officer · since 2023
Yao Jen Tu
General Manager, Chief Executive Officer-Zhuke · since 2025
Chin Chang Yang
Chairman of the Board · since 2025
Qiaoyun Xu
Head of Finance & Accounting · since 2022
Yihong Yang
Corporate Governance Officer · since 2023
Wenxiang Cai
Director · since 2020
Lisi Cai
Director · since 2005
Yicheng Chen
Director · since 2002
Director · since 2020
Director · since 2014
Director · since 2008
Yueqin Ye
Director · since 2005
Yigong Cai
Independent Director · since 2020
Mingliang Gao
Independent Director · since 2017
Independent Director · since 2011
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||